Phase 2 Established Dose from prior study, NCT03810196

5 treatments and conditions followed through the public trial records. Not medical advice. How a status is set

Treatments and conditions

Phase 2 Established Dose from prior study, NCT03810196
Treatment and conditionWhere it standsTrials
Phase 2 Established Dose from prior study, NCT03810196 for anemia, refractory, with excess of blastsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Phase 2 Established Dose from prior study, NCT03810196 for congenital bone marrow failure syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Phase 2 Established Dose from prior study, NCT03810196 for hemoglobinopathiesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Phase 2 Established Dose from prior study, NCT03810196 for immunologic deficiency syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Phase 2 Established Dose from prior study, NCT03810196 for metabolism, inborn errorsPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1